8. Huntington disease Clinical trials / Disease details

Clinical trials : 229 / Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02509793 (ClinicalTrials.gov)	August 1, 2018	24/7/2015	A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)	A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)	Huntington's Disease	Drug: Tetrabenazine	William Ondo, MD	H. Lundbeck A/S	Recruiting	18 Years	80 Years	All	20	Phase 4	United States
2	NCT01834911 (ClinicalTrials.gov)	March 2013	15/4/2013	Effect of Tetrabenazine on Stroop Interference in HD	Effect of Tetrabenazine on Stroop Interference in Huntington Disease	Huntington Disease	Drug: Tetrabenazine withdrawal	New York Medical College	NULL	Completed	18 Years	N/A	All	2	Phase 4	United States
3	NCT00632645 (ClinicalTrials.gov)	April 2009	29/2/2008	Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride	Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study.	Huntington Disease	Drug: Olanzapine;Drug: Xenazine;Drug: Tiapridal	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	N/A	All	180	Phase 3	France
4	NCT00219804 (ClinicalTrials.gov)	January 2000	14/9/2005	Efficacy and Safety of Tetrabenazine in Chorea	A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea	Huntington's Disease	Drug: tetrabenazine or placebo	Prestwick Pharmaceuticals	NULL	Completed	18 Years	N/A	Both		Phase 3	NULL